source
- FDA selects Dexcom as first participant in TEMPO digital health pilotThe U.S. Food and Drug Administration announced that Dexcom, Inc. has been chosen as the inaugural manufacturer for the Technology-Enabled Meaningful Patient Outcomes (TEMPO) pilot focused on digit…
- Safety and Toxicity Management in Metastatic Castration-Resistant Prostate CancerDr. Johann De Bono and Dr. Pedro Barata discuss practical approaches to monitoring and managing toxicities associated with radiopharmaceutical therapies in metastatic castration-resistant prostate…onclive · 3mo ago↗ source